The stock's overall trend over the past six months has been negative, with a decline of 10.05% from October 2025 to March 2026. The price peaked near $115 in early February 2026 before a sharp correction, indicating significant volatility and a lack of sustained upward momentum. Short-term performance shows continued weakness, with the stock down 8.56% over the past month, underperforming the S&P 500 which fell 7.87%. However, over the last three months, the stock's decline of 2.16% has been less severe than the broader market's 7.32% drop, suggesting some relative resilience in the recent quarter. As of the latest close, the stock price of $97.20 sits near the lower end of its 52-week range of $95.06 to $119.85, approximately 19% below its yearly high. The provided beta of 0.34 indicates the stock has historically been less volatile than the overall market.

Revenue growth has been positive on a year-over-year basis, with the most recent quarter (Q1 2026) showing a 10.1% increase to $2.17 billion compared to the same quarter a year prior. Profitability has been variable; the net margin improved to 4.45% in Q1 2026 from 2.27% in the previous quarter (Q4 2025), but remains below the 5.74% margin from Q1 2025. Financial health is characterized by significant leverage, with a debt-to-equity ratio of 2.05. However, the company maintains a strong current ratio of 1.67 and generates substantial free cash flow, with TTM free cash flow reported at $436 million, providing some cushion for its debt obligations. Operational efficiency metrics show a return on equity (ROE) of 8.94% and a return on assets (ROA) of 4.20%. These figures indicate moderate but positive returns on shareholder equity and company assets, though there is room for improvement in capital efficiency.